Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax: 2023-2024

  • ARS Pharmaceuticals' Long-Term Deferred Tax rose 26.92% to $36.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.9 million, marking a year-over-year increase of 26.92%. This contributed to the annual value of $36.9 million for FY2024, which is 26.92% up from last year.
  • As of Q4 2024, ARS Pharmaceuticals' Long-Term Deferred Tax stood at $36.9 million, which was up 26.92% from $29.0 million recorded in Q4 2023.
  • In the past 5 years, ARS Pharmaceuticals' Long-Term Deferred Tax registered a high of $36.9 million during Q4 2024, and its lowest value of $29.0 million during Q4 2023.
  • For the 2-year period, ARS Pharmaceuticals' Long-Term Deferred Tax averaged around $33.0 million, with its median value being $33.0 million (2023).
  • Data for ARS Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY rose of 26.92% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows ARS Pharmaceuticals' Long-Term Deferred Tax stood at $29.0 million in 2023, then rose by 26.92% to $36.9 million in 2024.